| dc.contributor.author | Musungu, Vincent | |
| dc.contributor.author | Onguru, Daniel | |
| dc.contributor.author | Onyango, Patrick | |
| dc.date.accessioned | 2024-03-13T16:10:01Z | |
| dc.date.available | 2024-03-13T16:10:01Z | |
| dc.date.issued | 2024-03-06 | |
| dc.identifier.issn | 2977-0335 | |
| dc.identifier.uri | https://repository.maseno.ac.ke/handle/123456789/6025 | |
| dc.description | https://doi.org/10.59652/aim.v2i1.112 | en_US |
| dc.description.abstract | Community-acquired pneumonia (CAP) is an important cause of mortality and morbidity worldwide. Early initiation of antibiotics is highly recommended. In most CAP cases, multiple drug options are increasingly becoming available, but there is often a lack of evidence that allows for a direct comparison of the efficacy of one drug versus another. | en_US |
| dc.publisher | European institute of knowledge and innovation | en_US |
| dc.subject | Levofloxacin, Azithromycin, Community acquired pneumonia, amoxycillin, clavulanic acid | en_US |
| dc.title | Comparative Efficacy of Levofloxacin Versus Amoxycillin/Clavulanic Acid Combined with Azithromycin in Treatment of Community-Acquired Pneumonia | en_US |
| dc.type | Article | en_US |
